×
For best experience we recommend to activate Javascript in your browser.
FRS2 antibody (AA 19-109)
This anti-FRS2 antibody is a Rabbit Polyclonal antibody detecting FRS2 in WB, ELISA and IHC. Suitable for Human.
Quick Overview for FRS2 antibody (AA 19-109) (ABIN7569322)
Target
See all FRS2 Antibodies
FRS2
(Fibroblast Growth Factor Receptor Substrate 2 (FRS2))
Reactivity
All reactivities for FRS2 antibodies
Human
Host
All hosts for FRS2 antibodies
Rabbit
Clonality
All clonalities for FRS2 antibodies
Polyclonal
Conjugate
All conjugates for FRS2 antibodies
This FRS2 antibody is un-conjugated
Application
All applications for FRS2 antibodies
Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
Product Details anti-FRS2 Antibody
(hide)
Binding Specificity
All epitopes for FRS2 antibodies
AA 19-109
Purpose
Anti-Human FRS2 Polyclonal Antibody
Purification
Antigen affinity purification.
Immunogen
E. coli - derived recombinant Human FRS2 (Asn19-Ser109).
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
0.01M PBS, pH 7.4, 50 % glycerol, 0.05 % Proclin 300.
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze thaw cycles.Store at 4°C for frequent use.Store at -20 to -80 °C for twelve months from the date of receipt.
Target Details for FRS2
(hide)
Target
FRS2
(Fibroblast Growth Factor Receptor Substrate 2 (FRS2))
Alternative Name
FRS2
Background
FGFR substrate 2, FRS2, Fibroblast growth factor receptor substrate 2, FGFR-signaling adaptor SNT, Suc1-associated neurotrophic factor target 1, SNT-1
UniProt
Q8WU20
Pathways
Fc-epsilon Receptor Signaling Pathway , EGFR Signaling Pathway , Neurotrophin Signaling Pathway , Signaling Events mediated by VEGFR1 and VEGFR2
Recently viewed
(hide)
Chat with us , powered by LiveChat